On this page
What evidence should a Fast Track designation request present?
For the ordinary serious-condition route, define the exact product and intended use, explain the serious condition and current unmet need, and show why the product has potential to address that need. Match the evidence to the development stage, describe limitations and explain how the planned program will evaluate the proposed benefit. A request does not establish designation.
Before you begin
FDA Fast Track designation for an identified product and indication under the serious-condition/unmet-need framework. QIDP-related statutory routes require their own established facts.
What you will prepare: A focused request with an evidence-based eligibility rationale and no assumed designation or approval.
Sections covered in this guide (2)
Define the condition, population and available therapy
Under the final guidance §V, the ordinary Fast Track analysis asks whether the drug is intended to treat a serious condition and whether it demonstrates potential to address an unmet medical need. Describe the proposed indication and population, the serious aspects of the condition and the available therapies relevant to that population. A general statement that a disease is burdensome does not establish the particular unmet need.
Build a comparison grounded in current evidence: treatment options, their limitations, the proposed product’s relevant attributes and the data supporting potential benefit. The type of evidence can depend on development stage. Do not present a mechanistic hypothesis as demonstrated clinical superiority, or substitute Breakthrough Therapy’s preliminary clinical-evidence test for Fast Track’s distinct criteria.
Make the designation request identifiable and supportable
Appendix 1 describes a request identifying the product, proposed indication, sponsor contact and the rationale for designation. Clearly identify the request in the cover letter and provide a concise, evidence-linked discussion of serious condition and unmet need. Submit in the appropriate IND context and coordinate with the responsible review division.
A useful narrative follows the decision: intended use; why the condition is serious; what current therapy leaves unresolved; why the product has potential to address that gap; evidence and limitations; specific designation requested. Include only the indication supported by the argument. A designation for one use should not be described as applying to all future uses of the molecule.
Keep later benefits and decisions separate
Fast Track can support more frequent communication and eligibility for rolling review, but rolling submission requires the relevant FDA assessment and agreement. Priority review and approval are separate determinations. The designation does not lower the evidentiary standard for approval.
Fictional exercise: a product is intended for a subset with inadequate response to existing therapy. The draft claims that no treatment exists for the entire disease. Correct the population and document the actual available-therapy gap. If the supporting data do not distinguish that subset, disclose the limitation and reassess the proposed indication rather than expanding the claim.
Keep the unmet-need argument tied to the intended use
Build the rationale around one defined indication and population. A persuasive description of a disease does not compensate for evidence that concerns a different treatment setting.
| Argument element | Evidence to assemble | Overstatement to remove |
|---|---|---|
| Serious condition | Relevant consequences for survival, functioning or progression | General burden without explaining the serious aspect |
| Available therapy | Current U.S. treatment context for the indication and disease stage | An obsolete comparator list or unsupported “no treatments” claim |
| Unmet need | Specific limitation that the proposed use addresses | A product attribute with no connection to patient need |
| Potential benefit | Stage-appropriate nonclinical, pharmacologic or clinical evidence | A mechanistic rationale described as demonstrated superiority |
| Evaluation plan | Studies that will assess the claimed potential | A gap named in the request but not tested in the development plan |
| Scope | Product, combination if applicable, and exact indication | One-use designation extended to the whole molecule |
The guidance's available-therapy discussion considers the current U.S. standard of care for the relevant indication. A treatment used in the broader population is not automatically irrelevant to a targeted subset. If the argument depends on poorer response in that subset, provide the evidence and limitations supporting that distinction. Use current product-specific sources when preparing a real request; this guide does not supply a live therapy assessment for an unnamed disease.
Stage-change exercise: an early request relied on a plausible mechanism and nonclinical activity. Clinical results are now available but do not measure the proposed unmet-need advantage. Do not retain the early rationale unchanged while omitting the new evidence. Explain what the clinical results do and do not show, and how the program will evaluate the relevant benefit. The guidance expects available clinical evidence to support potential unmet-need benefit later in development.
Appendix 1.A describes requesting designation with an initial IND or afterward before marketing approval, and ordinarily no later than the pre-NDA/pre-BLA meeting if its development benefits are to be useful. Preserve the actual request and decision dates. A designation for another indication calls for a separate supported request, not a silent extension of the first letter.
Keep rolling review as its own agreement task and use the designation correspondence guide when facts or plans change.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does Fast Track always require preliminary clinical evidence?
Its evidence can depend on development stage. The guidance allows early potential to be supported by nonclinical activity, a mechanistic rationale or pharmacologic data, while later available clinical data should support the unmet-need potential. Do not confuse this with Breakthrough Therapy designation’s distinct preliminary-clinical-evidence criterion.
Does Fast Track for one indication cover every use of the product?
No. The designation applies to the product and specific use being studied, including the defined combination where applicable. If new evidence supports designation for another indication, the guidance describes a separate request. Preserve each indication’s rationale and actual agency decision instead of treating the molecule as universally designated.
Does a rare disease automatically qualify a product for Fast Track?
No automatic conclusion follows from rarity alone under the ordinary framework discussed here. The request must support a serious condition and the product’s potential to address unmet need for the proposed use. Define the population, treatment context and evidence rather than substituting a disease label for that analysis.
Does Fast Track guarantee priority review or FDA approval?
No. Priority review is a separate determination, and FDA still assesses the evidence required for marketing approval. Fast Track can facilitate development interactions and potential rolling review, but those features do not establish a favorable final benefit-risk conclusion or an agreed schedule for submitting application portions.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
Expedited Programs for Serious Conditions: Drugs and Biologics ↗Final May 2014; Fast Track §§V, IX and Appendices 1–2. PDF reopened September 22, 2026; not used to freeze unrelated accelerated-approval policy.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.7. A heading identifies placement, not mandatory applicability.